Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
RaQualia Pharma Inc. (4579.T)
Nagoya, JP
RaQualia Pharma Inc., established in 2008 and based in Nagoya, Japan, is a pharmaceutical company dedicated to the global research and development of innovative drug compounds. Its human therapeutic pipeline features several key candidates. Tegoprazan, designed to treat gastroesophageal reflux disease (GERD), is currently undergoing Phase 1 clinical trials in the United States. Grapiprant is in Phase II development in the U.S. and Phase I in China for pain management; it is also being investigated in Phase I studies in both the U.S. and China for its potential in cancer therapy. Beyond human medicines, RaQualia Pharma develops a range of veterinary products. These include grapiprant for managing osteoarthritis in dogs, a ghrelin receptor agonist aimed at addressing cancer-related anorexia/cachexia syndrome and constipation stemming from spinal cord injury, and ELURA, a medication for combating weight loss in cats suffering from chronic kidney disease. The company's extensive R&D pipeline also covers various other therapeutic areas. This includes a TRPM8 blocker for neuropathic pain, a motilin receptor agonist targeting gastrointestinal motility disorders such as gastroparesis, functional dyspepsia, and post-operative ileus, and a potassium-competitive acid blocker for GERD, which has successfully concluded Phase 1 clinical trials. Further early-stage developments encompass a 5-HT4 partial agonist for gastroparesis, functional dyspepsia, and chronic constipation; a 5-HT2B antagonist for irritable bowel syndrome with diarrhea; EP4 antagonists for canine pain management and, in separate Phase I trials, for cancer and general pain indications; a serotonin 5-HT2A and dopamine D2 receptor blocker for schizophrenia; a Cyclooxygenase-2 inhibitor (Phase I for pain); a CB2 agonist; a selective sodium channel blocker; a P2X7 receptor antagonist (Phase I for neuropathic pain); and a retinoic acid receptor alpha agonist. To further its research and development initiatives, RaQualia maintains strategic partnerships with Interprotein Corporation, ASKA Pharmaceutical Co., Ltd., and Epigeneron, Inc.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -13.17% | -21.52% | -27.57% | -38.31% | +14.60% | -36.21% | +16.98% | -18.42% | -35.82% | +37.47% | -58.67% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+28.1% ★ Q1'26: -16.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+149.7% ★ Q1'26: -3,583.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-12.5% Q1'26: +30.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+12.2% ★ Q1'26: -20.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+4.6% ★ Q1'26: -10.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+11.1% Q1'26: +16.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×2.99× ★ Q1'26: -14.29× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
744.52M
est: 753.00M (-1.1%)
|
1.70B
est: 1.70B (+0.1%)
|
1.11B
est: 1.11B (+0.0%)
|
2.78B
est: 2.01B (+38.1%)
|
2.92B
est: 2.63B (+11.1%)
|
1.90B
est: 2.30B (-17.3%)
|
3.11B
est: 4.32B (-28.0%)
|
3.98B
est: 3.86B (+3.2%)
|
4.59B
4.59B – 4.59B
+19.0% YoY
|
4.64B
4.64B – 4.64B
+1.1% YoY
|
5.17B
5.17B – 5.17B
+11.3% YoY
|
| EBITDA |
-950.00M
est: 52.80M (-1,899.1%)
|
124.00M
est: 119.35M (+3.9%)
|
-403.25M
est: 77.63M (-619.5%)
|
1.02B
est: 140.95M (+626.2%)
|
1.00B
est: 184.15M (+445.6%)
|
-111.80M
est: 440.75M (-125.4%)
|
188.27M
est: 827.80M (-77.3%)
|
971.88M
est: 739.57M (+31.4%)
|
879.78M
879.78M – 879.78M
+19.0% YoY
|
889.75M
889.75M – 889.75M
+1.1% YoY
|
990.64M
990.64M – 990.64M
+11.3% YoY
|
| EBIT |
-1.08B
est: -12.77M (-8,317.8%)
|
-15.94M
est: -28.87M (+44.8%)
|
-527.50M
est: -18.77M (-2,709.7%)
|
882.03M
est: -34.09M (+2,687.4%)
|
857.01M
est: -44.54M (+2,024.3%)
|
-287.37M
est: 235.83M (-221.9%)
|
-213.38M
est: 442.93M (-148.2%)
|
483.72M
est: 395.72M (+22.2%)
|
470.74M
470.74M – 470.74M
+19.0% YoY
|
476.08M
476.08M – 476.08M
+1.1% YoY
|
530.06M
530.06M – 530.06M
+11.3% YoY
|
| Net Income |
-1.10B
est: -1.34B (+17.4%)
|
5.34M
est: 6.49M (-17.7%)
|
-606.99M
est: -627.72M (+3.3%)
|
755.79M
est: 259.75M (+191.0%)
|
723.39M
est: 290.05M (+149.4%)
|
-323.66M
est: -746.04M (+56.6%)
|
-495.03M
est: 567.39M (-187.2%)
|
273.12M
est: 627.49M (-56.5%)
|
1.16B
1.16B – 1.16B
+85.4% YoY
|
988.12M
988.12M – 988.12M
-15.1% YoY
|
1.29B
1.29B – 1.29B
+30.9% YoY
|
| SGA |
655.60M
est: 231.49M (+183.2%)
|
591.86M
est: 523.24M (+13.1%)
|
522.92M
est: 340.32M (+53.7%)
|
620.30M
est: 617.92M (+0.4%)
|
571.54M
est: 807.30M (-29.2%)
|
620.95M
est: 626.20M (-0.8%)
|
991.24M
est: 1.18B (-15.7%)
|
1.18B
est: 1.05B (+12.7%)
|
1.25B
1.25B – 1.25B
+19.0% YoY
|
1.26B
1.26B – 1.26B
+1.1% YoY
|
1.41B
1.41B – 1.41B
+11.3% YoY
|
| EPS |
-54.23
est: -61.80 (+12.2%)
|
0.26
est: 0.30 (-13.3%)
|
-28.97
est: -29.00 (+0.1%)
|
36.07
est: 12.00 (+200.6%)
|
34.50
est: 13.40 (+157.5%)
|
-14.98
est: -31.03 (+51.7%)
|
-22.87
est: 23.60 (-196.9%)
|
11.53
est: 26.10 (-55.8%)
|
48.40
48.40 – 48.40
+85.4% YoY
|
41.10
41.10 – 41.10
-15.1% YoY
|
53.80
53.80 – 53.80
+30.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B- | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | B- | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | B- | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | B- | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | B- | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | B- | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | B- | 2/5 | 2/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-01 | C+ | 2/5 | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C+ | 2/5 | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C+ | 2/5 | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C+ | 2/5 | 2/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 2/5 | 3/5 | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 2/5 | 3/5 | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | B- | 2/5 | 3/5 | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | B- | 2/5 | 3/5 | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hidefumi Sugiyama | GM of Finance & Accounting Department | — | — |
| Katsuhiro Uto | VP, Head of Research and Development & Director | — | — |
| Kiyoshi Kawamura | Executive Officer | — | — |
| Masaki Sudo | President & Chairman of Board | — | male |
| Motonori Shimizu | Executive Officer | — | male |
| Toshiyuki Saito | Executive Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4579.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
